- GW-1100
-
- $29.00 / 1mg
-
2025-12-22
- CAS:306974-70-9
- Min. Order:
- Purity: 97.01%
- Supply Ability: 10g
- GW-1100
-
- $7.00 / 1KG
-
2019-07-06
- CAS: 306974-70-9
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 100KG
|
| | GW-1100 Basic information |
| | GW-1100 Chemical Properties |
| Melting point | 208-210℃ | | Boiling point | 690.2±65.0 °C(Predicted) | | density | 1.29±0.1 g/cm3(Predicted) | | storage temp. | +2C to +8C | | solubility | Soluble in DMSO (up to 2 mg/ml) or in DMF (up to 5 mg/ml). | | form | White powder | | pka | 1.20±0.22(Predicted) | | color | White | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or DMF may be stored at -20° for up to 3 months. Dilutions into aqueous media are not stable and should be used within one working day. |
| | GW-1100 Usage And Synthesis |
| Description | GW1100 (306974-70-9) is a selective antagonist of GPR40. GW1100 inhibits GRP40-mediated Ca2+?increases stimulated by GW9508 (Cat.# 10-1108) or linoleic acid (pIC50?= 5.99 for either agonist).1?The effects of GPR40 activation on insulin secretion in cells are also blocked by the addition of GW1100. GW1100 does not influence calcium mobilization mediated by GPR120. | | Uses | GW 1100 is a selective G protein-coupled receptor GPR40 antagonist. GW 1100 has been shown to reverse the effects GPR40 agonists which induce glucose-stimulated insulin secretion. | | Biological Activity | GW-1100 is a selective GPR40 antagonist with pIC50 of 6.9. | | in vitro | GW-1100 (GW1100) dose dependently inhibits GPR40-mediated Ca 2+ elevations stimulated by GW9508 and linoleic acid (pIC 50 values of 5.99±0.03 and 5.99±0.06, respectively). GW-1100 at a concentration of 1 μM produces a significant rightward shift in the concentration-response curve to GW9508 (pEC 50 =7.17±0.08 in the absence and pEC 50 =6.79±0.09 in the presence of 1 μM GW-1100; P<0.05; n=3). At concentrations of GW-1100 of 3 μM and higher a significant decrease in the maximal response is observed with a continuing rightward shift in the pEC 50 response. GW-1100 (GW1100) reduces FFAR1 ligand-induced intracellular calcium in CHO-K1/bFFAR1 cells and neutrophils. CHO-K1/bFFAR1 cells are incubated for 15 min with 10 μM GW1100 or vehicle (0.1% DMSO) and then stimulated with vehicle, oleic acid, linoleic acid or GW9508. GW-1100 significantly reduces the increase in intracellular calcium induced by 300 μM oleic acid (AUC (60-150 s) , p<0.05), 100 μM linoleic acid (AUC (60-150 s) , p<0.05) and 10 μM GW9508 (AUC (60-150 s) , p<0.05). | | in vivo | The intracerebroventricular injection of DHA (50 μg) and GW9508 (1.0 μg), a GPR40-selective agonist, significantly reduces mechanical allodynia and thermal hyperalgesia at day 7, but not at day 1, after CFA injection. These effects are inhibited by intracerebroventricular pretreatment with GW-1100 (10 μg), a GPR40 antagonist. | | References | [1] CELIA P BRISCOE. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules[J]. British Journal of Pharmacology, 2009, 148 5: 619-628. DOI:10.1038/sj.bjp.0706770
[2] TAKAHIRO NAGATAKE PHD , PHD Tetsuya H M, PHD , et al. The 17,18-epoxyeicosatetraenoic acid–G protein–coupled receptor 40 axis ameliorates contact hypersensitivity by inhibiting neutrophil mobility in mice and cynomolgus macaques[J]. Journal of Allergy and Clinical Immunology, 2018, 142 2: Pages 470-484.e12. DOI:10.1016/j.jaci.2017.09.053 |
| | GW-1100 Preparation Products And Raw materials |
|